TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04760418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
Description: A 12-session integrated cognitive behavioral therapy for posttraumatic stress disorder and substance use

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
Description: A 12-session integrated cognitive behavioral therapy for posttraumatic stress disorder and substance use
Study: NCT06442150

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-Calorie Medicine Diet
Description: Low-Calorie Medicine Diet meals which are 815-835 kcal/day (approximately 43% carbohydrate, 29% protein, and 29% fat), combined with physical activity.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Low-Calorie Diet
Description: Low-Calorie Diet meals which are 815-835 kcal/day (approximately 43% carbohydrate, 29% protein, and 29% fat), combined with physical activity.
Study: NCT05066724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: 400 mg total daily dose Centanafadine Sustained Release, oral tablets
Study: NCT05777226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epalrestat
Description: Patients in the treatment group are intervened with Epalrestat tablets.
Study: NCT05222282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual Health
Description: Prevention of sexual dysfunction

Intervention type: OTHER
Group type: OTHER
Intervention: Sexual Health
Description: Prevention of sexual dysfunction
Study: NCT05737082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2201
Description: Take 2 tablets once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2201
Description: Take 2 tablets once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2205
Description: Take 2 tablets once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2205
Description: Take 2 tablets once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2206
Description: Take 1 tablet once per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2206
Description: Take 1 tablet once per period
Study: NCT04859608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spacing of Eculizumab infusions
Description: Personalized spacing of eculizumab infusions using a pharmacokinetic population model to estimate eculizumab concentration ( a one-week spacing of eculizumab infusion will be decide if predicted eculizumab concentration in the event of spacing is \> 150 mg/L). Spacing of infusion can be decided every 3 months.
Study: NCT06124040

Intervention type: BEHAVIORAL
Intervention: psychological assessment evaluation
Description: A prospective data collection will be performed with self-administered psychological measures, with the aim to compare two different groups of patients with cervical cancer neo diagnosis, candidates for non conservative surgery or radio-chemotherapy treatment, based on FIGO Gynecologic Oncology Committee Guidelines.~Test will be repeated at Time 0 (firs access in radiotherapy Day Hospital, or first access in hospital ward for surgery), and Time 1 (after 6 months).

Intervention type: BEHAVIORAL
Intervention: psychological assessment evaluation
Description: A prospective data collection will be performed with self-administered psychological measures, with the aim to compare two different groups of patients with cervical cancer neo diagnosis, candidates for non conservative surgery or radio-chemotherapy treatment, based on FIGO Gynecologic Oncology Committee Guidelines.~Test will be repeated at Time 0 (firs access in radiotherapy Day Hospital, or first access in hospital ward for surgery), and Time 1 (after 6 months).
Study: NCT05060016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Intravenous (IV) infusion
Study: NCT06652971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379
Description: QD, PO
Study: NCT05904730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: The starting dose of axitinib is 5 mg twice daily by mouth with meals. (reception is desirable at the same time every day)
Study: NCT06652815

Intervention type: BEHAVIORAL
Intervention: Suicide ideation or suicide attempt
Description: Individuals with high suicide ideation or suicide attempts visiting ABVIMS -Dr. RML Hospital for treatment will be screened for this study. socio- demographics details will also be gathered. Following this Depression, Anxiety and Stress Scale (DASS-21), Wisconsin Card Sorting Test (WCST), Metacognitions Scale (MCQ-30) and Stigma of Suicide Scale (SOSS) will be administered.
Study: NCT05972772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycyclin
Description: 100-mg film-coated tablets; Pfizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 250-mg capsules; Pfizer
Study: NCT06439082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Description: Crizanlizumab is supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion.
Study: NCT05385575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (0.1mg)
Description: The participants will receive assigned single dose of KN056 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (0.3mg)
Description: The participants will receive assigned single dose of KN056 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (1.0mg)
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (3.0mg)
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (6.0mg)
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (12.0mg)
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN056 (18.0mg)
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Study: NCT06590428

Intervention type: OTHER
Group type: OTHER
Intervention: Therapeutic Drug Monitoring for Linezolid
Description: TDM with dose adjustment for trough concentration \>2.5 mg/L LZD
Study: NCT05258279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion Q3W
Study: NCT06328556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection
Description: Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once. Using an ultrasound probe to scan the neck, the position of the lowest point, highest point, and lower middle point of the esophageal high-pressure zone are determined, and marks are made on the body surface and catheter wall. The high-pressure point and the lower middle point are selected as injection sites on the left side. The above area is locally disinfected, and the probe is covered with a sterile cover and coated with sterile coupling agent. Using a plane approach, 0.3ml or 30 unit of botulinum toxin is injected separately after reaching the esophageal circular layer at each of the two left injection points. A total of 60 unit of botulinum toxin is injected at the two left points.
Study: NCT06669169

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jia Shen Tablet Placebo
Description: Jia Shen Tablet Placebo contains 4 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks
Study: NCT06247605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL8326 tablets
Description: 10mg/tablet, Oral administration, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral administration, once daily.
Study: NCT05020665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: 400 mg, Orally as tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Continuous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: Continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline
Description: Either daunorubicin or idarubicin was administered via slow intravenous (IV) push

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anthracycline
Description: Either daunorubicin or idarubicin was administered via slow intravenous (IV) push
Study: NCT04728841

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Injection of GS001
Description: Patients will be enrolled sequentially every 3 weeks or more between cohorts. Dose escalation may occur after a single patient has been safely dosed if the resulting FVIII activity at Week 3 is \< 5 IU/dL.The dose levels are as follows:~1. 2×10\^12 vg/kg~2. 6×10\^12vg/kg or other recommended doses~3. 2×10\^13 vg/kg or other recommended doses
Study: NCT05007431

Intervention type: OTHER
Intervention: Questionnaires
Description: Data collection will be carried out by hetero-questionnaire carried out in the presence of the questioned.
Study: NCT04974996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally via tablet or capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally via tablet or capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV) infusion
Study: NCT06646185

Intervention type: OTHER
Group type: OTHER
Intervention: Menstrual Cups
Description: Participants adopt menstrual cups to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.

Intervention type: OTHER
Group type: OTHER
Intervention: Menstrual Cups
Description: Participants adopt menstrual cups to manage their menstruation during 2 menstrual cycles. For each menstrual cycle, participants will provide vaginal microbiome samples via self-sampled swabs at 3 points.
Study: NCT04974996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Intravenous (IV) infusion
Study: NCT06099522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Description: The treatment is a newly developed iCBT 8 module program, with interventions targeting gambling-related loss of control, through 4 clinical processes: Gambling triggers, Gambling-related anticipation, the Gambling zone and Chasing behaviors. The treatment will be delivered with therapist support.
Study: NCT06669169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Jia Shen Tablet
Description: Low dose Jia Shen Tablet contains 2 tablets (0.47 g per tablet) and 2 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Jia Shen Tablet
Description: High dose Jia Shen Tablet contains 4 tablets (0.47 g per tablet),take orally, 2 times a day for 12 weeks
Study: NCT06670235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Upright Birthing Position
Description: This intervention involves encouraging participants to use an upright position during labor and delivery, which may include : squatting, based on their preference and comfort level. Healthcare staff will support the participants in maintaining an upright position throughout labor as much as possible to evaluate its effects on maternal and newborn outcomes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lithotomy Birthing Position
Description: Participants in this arm will be positioned in the lithotomy position during labor and delivery, which is a common practice in clinical settings. In this position, the mother lies on her back with her legs supported in stirrups. This intervention serves as the control condition to provide a baseline comparison for evaluating outcomes against the upright birthing position.
Study: NCT06607627

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Gefurulimab
Description: Combination product consisting of syringe prefilled with gefurulimab will be administered weekly via subcutaneous (SC) injection.
Study: NCT06140199

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pit-picking surgery
Description: Patients are placed in left-side position. After shaving, cleaning and scrubbing of the skin with alcoholic chlorhexidine, double strong tape is placed on the right buttock in order to increase exposure. Local anaesthesia is administered before incision with 20 ml xylocaine or lidocaine 1-2%. In principle, all sinusoidal pits are cut out with a margin of at least 1 mm with a biopsy core punch (4 mm, 6 mm or 8 mm depending on pit size) or an oval excision of the pits is performed. Hair and debris is removed from the sinus tracts with a small surgical spoon or mosquito clamp. Rigorous de-epithelialisation of the underlying sinus is performed with the spoon through every pit, whilst removing even more debris and hairs. At the end of the procedure a debris washout is performed with saline solution, the wounds are left open for secondary healing and sterile dressings are applied.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pit-picking surgery with Sinus Laser assisted Closure
Description: The pit picking procedure is described above. Subsequently, a radial diode laser probe at 1470 nm wavelength is used for delivering homogeneous (360 degrees) energy to the surrounding epithelium. The laser energy is 13 Joule, given continuously. First, a 'preparatory laser treatment' is performed to extract any missed hairs or debris, after which the sinus tracts are cleansed with a surgical spoon again. During the following definitive procedure, the probe is withdrawn at an approximate speed of 1 cm per three seconds, causing the small sinus tracts to shrink and close. Large sinus tracts remain open because very large sinus tracts or cavities cannot be closed with the 3mm laser fibre. The injury to the endothelium will cause granulation and create oedema for collapsing of the tract. The remaining open wounds are left open for secondary healing and sterile dressings are applied.
Study: NCT05338333

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal contact lenses
Description: Investigational frequent replacement soft contact lens indicated for the optical correction of presbyopia

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal contact lenses
Description: Investigational frequent replacement soft contact lens indicated for the optical correction of presbyopia

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses
Description: Commercially available frequent replacement soft contact lens indicated for the optical correction of presbyopia

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses
Description: Commercially available frequent replacement soft contact lens indicated for the optical correction of presbyopia

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE®
Description: Hydrogen peroxide-based contact lens cleaning and disinfecting solution

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE®
Description: Hydrogen peroxide-based contact lens cleaning and disinfecting solution
Study: NCT06657937

Intervention type: OTHER
Intervention: Questionnaire
Description: An initial questionnaire is completed on D0, the day of the patient's admission to the emergency department, by the practitioner in charge of the patient, and covers the patient's anamnesis, clinical examination, radiological examinations and treatment.~A follow-up telephone visit is then carried out at 30 days by an investigator, to gather information on the clinical and therapeutic evolution, and to evaluate the recovery and evolution of symptoms experienced by the patient in relation to the initial management.
Study: NCT03201939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: ACE-inhibitor (lisinopril)(intervention arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Comparator placebo (control arm)
Study: NCT06616857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NUDGE
Description: Individuals in this condition will receive intervention content to promote physical activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Individuals will receive educational materials about how to increase physical activity
Study: NCT06664892

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated radiation
Description: RT, delivered via external beam, 5.2 Gy per fraction for 5 fractions following BCS and neoadjuvant or adjuvant chemotherapy. Specific adjuvant/neoadjuvant therapies are at the discretion of the treating Medical Oncologist.
Study: NCT06208852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Navigator Program
Description: For the intervention phase of the sub-study, 30 women with persistent PPD symptoms will be recruited to participate in the adapted virtual navigator program using rapid cycle testing over a 2-month period. These women will be enrolled and consented to receive virtual patient navigation for 2 months. Investigators will conduct rapid cycle testing in which we will evaluate satisfaction, feasibility, and target engagement of the intervention after every 10 participants in order to make rapid cycle changes prior to enrolling the next 10 participants. Women will communicate virtually with the PN by means of telephone, text messaging, Facetime, or other virtual modality of their choice. The Primary Navigator (PN) will meet with families at the beginning of the study to review results of depression screens and community mental health (MH) resources. The PN will partner with participants, engage them in the program, and provide ongoing communication with participants and MH clinicians.
Study: NCT06614127

Intervention type: DEVICE
Intervention: Dexcom G7® sensor placed in upper arm and positioned over deltoid
Description: For the subjects with Dexcom G7® sensor placed in the upper arm and positioned over the deltoid cohort, study personnel will place the Dexcom G7® sensor on the subjects' deltoid and the electrodispursive pad on the thigh.

Intervention type: DEVICE
Intervention: Dexcom G7® sensor placed in anterior thigh
Description: For the subjects with Dexcom G7® sensor place in anterior thigh cohort, study personnel will place the Dexcom G7® sensor in the anterior thighs and the electrodispursive pad will be placed on the opposite thigh.
Study: NCT04602728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back2Life
Description: The Back2Life intervention uses an adaptive treatment approach with module-based treatment sessions selected on the basis of baseline assessment (rather than a fixed treatment approach) to allow flexibility in tailoring treatment components to meet individual family needs. All youth participants will receive the standard 6-session pain coping skills training program, consisting of learning ways to cope with and manage chronic sickle cell pain. The standard program includes topics that were identified by young people with chronic sickle cell pain and their parents as important skills for all youth with chronic pain and sickle cell disease. In addition to the standard 6-session program, youth participants may receive an additional 1 to 4 sessions that may help with specific problems and/or co-morbidities related to pain. At least one parent or guardian is required to attend the sessions with their child.
Study: NCT06482307

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-olaparib PET scan
Description: The IMP investigated is \[18F\]Olaparib, a radiolabelled PARP inhibitor suitable for PET imaging.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-olaparib PET scan
Description: The IMP investigated is \[18F\]Olaparib, a radiolabelled PARP inhibitor suitable for PET imaging.
Study: NCT06619912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine nasal spray
Description: Participants will be randomised to receive either dexmedetomidine or saline nasal spray (1.5ug/kg) at the night before surgery and 30 minutes before induction.
Study: NCT05112900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging (TM)
Description: \[see arm/group descriptions\]

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging + Health Navigation (TM+HN)
Description: \[see arm/group descriptions\]